Loading...
Loading...
CRDL| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 14.1M |
| Operating I/L | -14.1M |
| Other Income/Expense | 1.4M |
| Interest Income | 0.2M |
| Pretax | -12.7M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -12.7M |
Cardiol Therapeutics Inc. is a clinical-stage life sciences company specializing in anti-fibrotic and anti-inflammatory therapies for cardiovascular disease. Their lead product, CardiolRx, is undergoing Phase II/III trials for cardioprotective therapy in COVID-19 patients and acute myocarditis. Additionally, the company is developing a subcutaneous formulation of CardiolRx for heart-related fibrosis and inflammation, targeting heart failure progression.
